Press Releases

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where

Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy

Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing protein Interim readout showed treatment with NTLA-2001 at 1.0

CAMBRIDGE, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji , R.Ph., to its board of

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading  T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of

CAMBRIDGE, Mass. , April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and

NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia CAMBRIDGE, Mass. , March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

Background In May 2012, the Regents of University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) filed a patent application for their CRISPR/Cas9 genome editing technology. The CVC team led by Drs. Jennifer Doudna and Emmanuelle Charpentier promptly brought

NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform    NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen frequently found in acute myeloid leukemia (AML) and other hematologic and

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated